logo
logo

RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines

Aug 24, 2020•almost 5 years ago

Amount Raised

$2 Million

Round Type

seed

Gaithersburg

Description

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announces today completion of its $2.35 million seed round financing from multiple venture capitalists including Terra Magnum Capital Partners. The Company will use the proceeds to advance its Covid-19 vaccine (RV1730) program and neoantigen-based cancer vaccine programs.

Company Information

Company

Rn Aimmune, Inc.

Location

Gaithersburg, Maryland, United States

About

RNAimmune is a biopharmaceutical company specializing in discovery and development of messenger RNA (mRNA) therapeutics and vaccines. The company leverages mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. RNAimmune is a spin-off venture from Sirnaomics, Inc. having received a global exclusive right to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery from Sirnaomics. The company has also developed a proprietary A.I. algorithm (ALEPVA) for antigen prediction and vaccine design. By integrating multiple established platform technologies, the company is aiming to develop a comprehensive mRNA drug discovery and development platform, from which the company will enrich its therapeutic and vaccine product pipeline addressing tremendous unmet needs in treatments of viral infections, cancer and rare diseases.  The company's headquarters are located in suburban Maryland and have a vision on the global market. Learn more at www.rnaimmune.com.

FundzWatch™ Score

62
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood